News | July 18, 2014

VISION Trial Evaluates First Imaging Atherectomy Catheter to Treat Peripheral Artery Disease

Avinger enrolls first PAD patient in VISION global clinical trial

July 18, 2014 — Avinger announced that John Pigott, M.D., of Jobst Vascular Institute, Toledo, Ohio, enrolled the first patient in the VISION trial, a global investigational device exemption (IDE) clinical trial approved by the U.S. Food and Drug Administration (FDA) to evaluate the Pantheris catheter for the treatment of peripheral artery disease (PAD).

The Pantheris system combines directional atherectomy capabilities with real-time intravascular visualization to remove plaque from blocked arteries. The minimally invasive catheter is designed to remove plaque, while avoiding the disruption of normal arterial wall structures.

“While today is a big day for Avinger, it’s an even bigger day for physicians and hospitals looking for better ways to treat patients suffering from vascular disease. Today we are one step closer,” said John B. Simpson, M.D., Ph.D., Avinger founder and CEO. “We designed Pantheris to help physicians better understand what is going on inside the artery as they are treating it. There isn’t a physician on the planet that doesn’t want more information about their patients’ disease state with the ability to act on it in real time.”

“For the first time ever, I am able to visualize the inside of the artery and selectively remove plaque without disrupting the healthy portion of the vessel. This has the potential to revolutionize the treatment of vascular disease,” added Pigott.

“We are convinced that Avinger’s Pantheris catheter will be a major step forward for our patients and for the entire medical community as the increased precision allowed by direct visualization is immediate and significant,” said VISION co-principal investigators William Crowder, M.D., and J. Gray Bennett, M.D., of St. Dominic Hospital, Jackson, Miss.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init